San Diego-based mostly Viking Therapeutics marked itself as a serious competitor within the weight loss drug current market in February soon after revealing promising data from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified like a weekly injection and in March t